<DOC>
	<DOCNO>NCT02565186</DOCNO>
	<brief_summary>This prospective , randomize , open-label study subject migraine complete CoLucid Phase 3 study , COL MIG 301 COL MIG-302 . The study design evaluate safety tolerability long-term intermittent use lasmiditan 100 mg lasmiditan 200 mg , first dose second dose , acute treatment migraine . Long term efficacy also evaluate .</brief_summary>
	<brief_title>An Open-label , Long-term , Safety Study Lasmiditan Acute Treatment Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . Able willing give write informed consent authorize HIPAA . 2 . Completed COL MIG301 COL MIG302 within last 4 week . 3 . Females childbearing potential must use willing use highly effective form contraception ( e.g . combine oral contraceptive , intrauterine device ( IUD ) , abstinence vasectomized partner ) . 4 . Able willing complete electronic diary record detail migraine attack treat study drug . 1 . Any medical condition clinical laboratory test judgment Investigator make subject unsuitable study . 2 . Pregnant breastfeed woman . 3 . Women childbearing potential use willing use highly effective contraception . 4 . Subject imminent risk suicide ( positive response question 4 5 C SSRS ) . 5 . Initiation change concomitant medication reduce frequency migraine episode since complete COL MIG301 COL MIG302 . 6 . Participation clinical trial experimental drug device since complete EoS/Visit 2 COL MIG 301 COL MIG302 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>